Have a feature idea you'd love to see implemented?
Let us know!
OLMA Olema Pharmaceuticals Inc
Price (delayed)
$11.72
Market cap
$671.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.06
Enterprise value
$656.23M
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is
Highlights
The debt has declined by 11% since the previous quarter and by 2.3% year-on-year
Olema Pharmaceuticals's equity has increased by 41% YoY but it has decreased by 3.9% from the previous quarter
OLMA's EPS is up by 15% YoY but it is down by 2.5% QoQ
OLMA's quick ratio is down by 20% year-on-year and by 5% since the previous quarter
Olema Pharmaceuticals's net income has decreased by 13% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of OLMA
Market
Valuations
Earnings
Shares outstanding
57.27M
Market cap
$671.16M
Enterprise value
$656.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.89
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$109.63M
EBITDA
-$108.05M
Free cash flow
-$92.42M
Per share
Balance sheet
Liquidity
EPS
-$2.06
Free cash flow per share
-$1.64
Book value per share
$4.06
Revenue per share
$0
TBVPS
$4.52
Total assets
$254.56M
Total liabilities
$27.39M
Debt
$1.96M
Equity
$227.16M
Working capital
$215.65M
Debt to equity
0.01
Current ratio
9.13
Quick ratio
9.01
Net debt/EBITDA
0.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.3%
Return on equity
-44.2%
Return on invested capital
-56.9%
Return on capital employed
-48.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OLMA stock price
How has the Olema Pharmaceuticals stock price performed over time
Intraday
-1.6%
1 week
-4.79%
1 month
-7.13%
1 year
2.09%
YTD
-16.46%
QTD
-1.84%
Financial performance
How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$121.63M
Net income
-$109.63M
Gross margin
N/A
Net margin
N/A
The operating income has decreased by 20% YoY and by 11% QoQ
Olema Pharmaceuticals's net income has decreased by 13% YoY and by 10% from the previous quarter
Growth
What is Olema Pharmaceuticals's growth rate over time
Valuation
What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.89
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is up by 15% YoY but it is down by 2.5% QoQ
Olema Pharmaceuticals's equity has increased by 41% YoY but it has decreased by 3.9% from the previous quarter
OLMA's price to book (P/B) is 11% more than its last 4 quarters average of 2.6
Efficiency
How efficient is Olema Pharmaceuticals business performance
The return on assets has grown by 15% year-on-year but it has declined by 2.5% since the previous quarter
Olema Pharmaceuticals's ROE has increased by 15% YoY but it has decreased by 3% from the previous quarter
The return on invested capital has grown by 6% year-on-year
Dividends
What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OLMA.
Financial health
How did Olema Pharmaceuticals financials performed over time
Olema Pharmaceuticals's total liabilities has soared by 71% YoY
Olema Pharmaceuticals's total assets has increased by 43% YoY but it has decreased by 3.5% from the previous quarter
The debt is 99% smaller than the equity
Olema Pharmaceuticals's equity has increased by 41% YoY but it has decreased by 3.9% from the previous quarter
The debt has declined by 11% since the previous quarter and by 2.3% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.